Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Nitroimidazoles
  • Phosphoramide Mustards
  • Sarcoma
  • Vascular Endothelial Growth Factor A

abstract

  • The combination of TH-302, VEGF-A inhibition, and RT is highly effective in preclinical models of sarcoma and is associated with increased DNA damage and apoptosis in endothelial cells and decreased HIF-1α activity.

publication date

  • June 30, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4647529

Digital Object Identifier (DOI)

  • 10.1038/bjc.2015.186

PubMed ID

  • 26010414

Additional Document Info

start page

  • 46

end page

  • 56

volume

  • 113

number

  • 1